- Report
- March 2024
- 180 Pages
Global
From €3242EUR$3,374USD£2,788GBP
€3602EUR$3,749USD£3,097GBP
- Report
- May 2024
- 189 Pages
Global
From €4756EUR$4,950USD£4,090GBP
- Clinical Trials
- April 2024
- 80 Pages
Global
From €1922EUR$2,000USD£1,652GBP
- Report
- January 2024
- 146 Pages
Global
From €4084EUR$4,250USD£3,511GBP
- Report
- July 2023
- 80 Pages
Global
From €3358EUR$3,495USD£2,888GBP
- Report
- November 2022
- 95 Pages
Global
From €5717EUR$5,950USD£4,916GBP
- Report
- November 2018
- 121 Pages
Global
From €2104EUR$2,190USD£1,809GBP
- Report
- April 2020
- 139 Pages
North America
From €2018EUR$2,100USD£1,735GBP
€2883EUR$3,000USD£2,479GBP
- Report
- April 2020
- 154 Pages
Europe
From €2018EUR$2,100USD£1,735GBP
€2883EUR$3,000USD£2,479GBP
- Report
- April 2020
- 147 Pages
Asia Pacific
From €2018EUR$2,100USD£1,735GBP
€2883EUR$3,000USD£2,479GBP
- Report
- August 2022
- 110 Pages
Global
From €4564EUR$4,750USD£3,924GBP
- Report
- January 2022
- 200 Pages
Global
From €7206EUR$7,500USD£6,197GBP
- Report
- January 2022
- 60 Pages
Global
From €3795EUR$3,950USD£3,264GBP
- Drug Pipelines
- January 2019
- 40 Pages
Global
From €1441EUR$1,500USD£1,239GBP
- Report
- August 2022
United States
From €1864EUR$1,940USD£1,603GBP
- Report
- August 2022
Global
From €951EUR$990USD£818GBP
- Report
- August 2021
Global
From €3834EUR$3,990USD£3,297GBP
- Report
- August 2021
Europe
From €3286EUR$3,420USD£2,826GBP
- Report
- February 2021
Global
From €2844EUR$2,960USD£2,446GBP
- Clinical Trials
- February 2020
- 105 Pages
Global
From €2402EUR$2,500USD£2,066GBP
Spinal Muscular Atrophy (SMA) is a rare genetic disorder that affects the motor neurons in the spinal cord, leading to progressive muscle weakness and wasting. As a result, individuals with SMA experience difficulty with activities of daily living, such as walking, eating, and breathing. Treatment for SMA is focused on managing symptoms and slowing the progression of the disease.
The SMA drug market is a subset of the Central Nervous System (CNS) drug market. CNS drugs are used to treat a variety of neurological disorders, including SMA. Currently, there are several drugs approved for the treatment of SMA, including Spinraza, Zolgensma, and Evrysdi. These drugs are designed to slow the progression of the disease and improve the quality of life for those affected.
Some of the companies in the SMA drug market include Biogen, Novartis, AveXis, and Roche. These companies are actively researching and developing new treatments for SMA, as well as providing access to existing treatments. Show Less Read more